Royalty Pharma plc reported excellent financial results for the second quarter of 2025 on August 6, 2025, with Portfolio Receipts growing by 20% to $727 million compared to $608 million in Q2 2024. Royalty Receipts increased by 11% to $672 million, driven by strong performance from Voranigo, Trelegy, Evrysdi, and Tremfya, along with a one-time payment in milestones and other contractual receipts.
The company raised its full year 2025 Portfolio Receipts guidance to a range of $2.975 billion to $3.125 billion, representing expected growth of 9% to 12%. This updated guidance reflects the strong performance of the diversified portfolio. Total interest paid in 2025 is anticipated to be approximately $275 million.
Royalty Pharma repurchased approximately eight million Class A ordinary shares for $277 million in Q2 2025, bringing total repurchases in the first half of 2025 to approximately 31 million shares for $1 billion. The company also successfully completed the acquisition of its external manager in May 2025, becoming an integrated company, and announced a $2 billion funding agreement with Revolution Medicines in June 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.